A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP ...

AbbVie’s hopes of getting a so-called PARP inhibitor cancer drug to market are fading after its veliparib failed in two late-stage studies. AstraZeneca’s Lynparza (olaparib) is becoming well ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. But after flunking three clinical trials with the combination, the company has emerged with a tepid win ...

Poly-(ADP-ribose) polymerase (PARP) inhibitors are the first clinical example of such synthetic lethality in tumors having specific DDR defects. They are currently under investigation as DDR ...

GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli ...

AstraZeneca and Merck & Co’s – known as MSD outside the US and Canada – olaparib already holds approvals to treat certain cases of prostate cancer under the brand name Lynparza. PARP inhibitors such ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. Days after Merck & Co. posted a disappointing result on patient survival from its PD-1/PARP combination of Keytruda and Lynparza ...

Poly (ADP-ribose) polymerase (PARP) inhibitors are used as maintenance therapy after completion of platinum-based ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

The PARP & DDR Inhibitors Summit is your only industry focused meeting dedicated to bringing DDR therapeutics to the clinic. The digital meeting will capitalize on the therapeutic application of ...